Detail akcie Pyxis Oncology Rg online

Business Summary: Pyxis Oncology, Inc. is a clinical-stage company focused on developing therapeutics to target difficult-to-treat cancers. The Company is building therapeutics that hold the potential for mono and combination therapies. Its clinical program portfolio includes micvotobart pelidotin (MICVO), PYX-106, Sotigalimab (PYX-107), PYX-203, PYX-102, and APX601. The Company’s lead product candidate, MICVO, is an antibody-drug conjugate (ADC) that targets Extradomain-B Fibronectin (EDB+FN), a non-cellular structural component of the tumor extra-cellular matrix (ECM). MICVO is designed to generate a multi-pronged attack on difficult-to-treat cancers by directly killing cancer cells, reducing ECM density, inhibiting tumor angiogenesis and mobilizing an anti-tumor immune response. The Company’s ADC, MICVO, consists of human Immunoglobulin G1 (IgG1) and is site-specifically conjugated with a cleavable linker and a microtubule inhibitor (optimized auristatin) payload.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Pyxis Oncology Inc revenues decreased 83% to $2.8M. Net loss increased 47% to $61.5M. Revenues reflect Royalty revenues decrease from $8.1M to $0K, Milestone Revenue decrease of 65% to $2.8M. Higher net loss reflects Biotechnology segment loss increase of 34% to $66.1M. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.70 to -$0.99.